191 related articles for article (PubMed ID: 29096381)
1. Epitopes based drug design for dengue virus envelope protein: A computational approach.
Wadood A; Mehmood A; Khan H; Ilyas M; Ahmad A; Alarjah M; Abu-Izneid T
Comput Biol Chem; 2017 Dec; 71():152-160. PubMed ID: 29096381
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach.
Aarthy M; Singh SK
Curr Top Med Chem; 2018; 18(18):1585-1602. PubMed ID: 30360716
[TBL] [Abstract][Full Text] [Related]
3. De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus.
Leal ES; Adler NS; Fernández GA; Gebhard LG; Battini L; Aucar MG; Videla M; Monge ME; Hernández de Los Ríos A; Acosta Dávila JA; Morell ML; Cordo SM; García CC; Gamarnik AV; Cavasotto CN; Bollini M
Eur J Med Chem; 2019 Nov; 182():111628. PubMed ID: 31472473
[TBL] [Abstract][Full Text] [Related]
4. Identification of sequence motifs involved in Dengue virus-host interactions.
Asnet Mary J; Paramasivan R; Shenbagarathai R
J Biomol Struct Dyn; 2016; 34(3):676-87. PubMed ID: 25905427
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.
Anasir MI; Ramanathan B; Poh CL
Viruses; 2020 Mar; 12(4):. PubMed ID: 32225021
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS
J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854
[TBL] [Abstract][Full Text] [Related]
7. Peptide inhibitors against dengue virus infection.
Panya A; Bangphoomi K; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2014 Aug; 84(2):148-57. PubMed ID: 24612829
[TBL] [Abstract][Full Text] [Related]
8. Development of Global Consensus of Dengue Virus Envelope Glycoprotein for Epitopes Based Vaccine Design.
Hussain M; Idrees M; Afzal S
Curr Comput Aided Drug Des; 2015; 11(1):84-97. PubMed ID: 26022067
[TBL] [Abstract][Full Text] [Related]
9. Screening of commercial cyclic peptides as inhibitor envelope protein dengue virus (DENV) through molecular docking and molecular dynamics.
Parikesit AA; Kinanty ; Tambunan US
Pak J Biol Sci; 2013 Dec; 16(24):1836-48. PubMed ID: 24516999
[TBL] [Abstract][Full Text] [Related]
10. A computational approach for identification of epitopes in dengue virus envelope protein: a step towards designing a universal dengue vaccine targeting endemic regions.
Chakraborty S; Chakravorty R; Ahmed M; Rahman A; Waise TM; Hassan F; Rahman M; Shamsuzzaman S
In Silico Biol; 2010; 10(5-6):235-46. PubMed ID: 22430357
[TBL] [Abstract][Full Text] [Related]
11. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
[TBL] [Abstract][Full Text] [Related]
12. Epitope prediction and designing of receptor inhibitor of Dengue Envelope Protein: An
Uttam G; Kumari A; Singh K
J Vector Borne Dis; 2023; 60(2):161-171. PubMed ID: 37417165
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors.
Jadav SS; Kaptein S; Timiri A; De Burghgraeve T; Badavath VN; Ganesan R; Sinha BN; Neyts J; Leyssen P; Jayaprakash V
Bioorg Med Chem Lett; 2015 Apr; 25(8):1747-1752. PubMed ID: 25791449
[TBL] [Abstract][Full Text] [Related]
14. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel dengue virus entry inhibitors via a structure-based approach.
Leal ES; Aucar MG; Gebhard LG; Iglesias NG; Pascual MJ; Casal JJ; Gamarnik AV; Cavasotto CN; Bollini M
Bioorg Med Chem Lett; 2017 Aug; 27(16):3851-3855. PubMed ID: 28668194
[TBL] [Abstract][Full Text] [Related]
16. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
[TBL] [Abstract][Full Text] [Related]
17. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
Wadood A; Riaz M; Uddin R; Ul-Haq Z
PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel target sites and an inhibitor of the dengue virus E protein.
Yennamalli R; Subbarao N; Kampmann T; McGeary RP; Young PR; Kobe B
J Comput Aided Mol Des; 2009 Jun; 23(6):333-41. PubMed ID: 19241120
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
20. Targeting the dengue β-OG with serotype-specific alkaloid virtual leads.
Gangopadhyay A; Chakraborty HJ; Datta A
J Mol Graph Model; 2017 May; 73():129-142. PubMed ID: 28279821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
